Agreement n°:

761297-JATC-HP-JA-03-2016

WP7 - D7.4

Report on a proposed system for the reporting of adverse effects

JAT(JOINT ACTION ON **TOBACCO CONTROL**

Circulation: Public Authors: WP7 partners, Led by ISS Date: 21/10/2019

Doc. Ref. N°: D7.4



This activity has received funding from the European Union's Health Program (2014-2020) under grant agreement - 761297.

The content of this publication represents the views of the author only and is his/ her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

Introduction

The EU Tobacco Products Directive (TPD) 2014/40/ EU9 along with Commission Implementing Decisions EU 2016/586 (2016)10 and EU 2015/2183 (2015)11, has established standards for e-cigarette reporting, product safety and packaging. Specifically, the provisions of EU TPD Article 20 enumerate product labelling, packaging, composition and technical requirements including, but not limited to, child-resistant packaging features, refill container volume, nicotine content levels, health warning labels, informational leaflets, and technical parameters to reduce the risk of spilling during refill or leaking during use.

The overall objective of Task 4.2 within this specific Work Package (WP) is to support the EU MS in the development of a system for the reporting of information of suspected adverse effects on human health inline with TPD Art.20(9).

This deliverable (D7.4) presents a short reporting template for the reporting of adverse effects both by economic operators (Annex 1) as also by competent authorities (Annex 2).





Annex 1. Short reporting template for the reporting of adverse effects for economic operators

Reporting form of suspected adverse effects (AE) for electronic cigarette (e-cig) and refill liquid											
Patient individual data											
1. Initials or Record number 2. Year of		of birth	3. Sex □ M □ F		4. Weight (kç	3)	5. Height (cm)				
6. Ethnicity/race (optional)			7.	Pregnancy Breastfeeding	□NO □YES, V	veek					
		Desc	riptio	n of AE							
8. AE start (date)		9. Causes of AE									
o. At sidif (ddie)				-cig explosion \Box poisoning from the refill liquid (by ingestion) \Box skin absorption							
			e-cig, describe								
10. Symptoms		11. If use of the e-cig was stopped did the AE stop?									
☐ throat irritation ☐ coughing	☐ headache	☐ NO ☐ YES									
\square sore throat \square bleeding	orm the nose	☐ dizziness	12. Treatment of the AE								
dry mouth anaphyla:	kis	☐ vertigo		□ NO □ YES							
☐ mouth ulcers ☐ sweating		☐ tremors		Describe							
☐ dry cough ☐ abdomind	Il pain	☐ restlessness									
☐ laryngospasm ☐ high blood	pressure	☐ tachycardia									
asthma vomiting		☐ bradycardia		13. Seriousnes	s of AE	14. O	utcome				
shortness of breath skin rash		eye irritation				_	<u> </u>				
bronchospasm anausea		nose irritation		required a visit to doctor			discharged after doctor visit				
'		burn and scalds		admitted to ho	ospital		☐ recovered,				
chest pain diarrhoea				disability			w long				
worsening of pre-existing conditions:				life threatenin	ng		al(date)				
other death unknown							known				
15. Comments on causal relationships between e-cig and AE certain likely possibile unlikely unrelated unknown note											
16. Describe any other detail (e.g. duration of the AE, complications/sequelae and any relevant laboratory results)											
17 Evolucive use of a sign	VEC. DINO	#	18	B. Use of E-cig co	ontainina						
The second secon											
	additional, nowlong										
Duration of smoking before e-cig start			☐ mixed substances								
19. Nicotine concentration (mg/ml):			20. Duration of e-cig use			21. F	Restart e-cig use after AE				
rechargeable e-cig (refillable through	ottle)	— less than 1 month □ 2-3 months				☐ YES ☐ NO					
disposable e-cig					:	Symptoms returned					
		4-6 months more than 6 months				☐ YES ☐ NO					
22. Is the electronic cigarette u		, ,		•		□NO					
Specify the brand											
If answered <u>NO</u> it changed: □ e-cig	□ carfridge	e 🖵 retill liquid 🖵 selt-made e	e-cig L	■ self-made/mixed li	quid note						
Specify the new brand (e-cig and/or	liquid)			Sales point if	different						
23. Medications, NRT and/or other products based on medicinal plants, homeopathic, food supplements etc. used at the time of the appearance of the AE UYES VES NO If YES Specify											
Dosage, route of administration and duration of use:											
24. Current or past relevant medical history (illnesses, allergies, alcohol use, drugs of abuse, etc.)											
Manufacturer, importer, distributor											
25.											
24	u.:. 4 · · · ·	Commenter to the tr	and a st		u						
26. date Send this form to: Competent authority or market surveillance authority											
1											

Annex 2. Short reporting template for the reporting of adverse effects for competent authorities

Reporting form of suspected adverse effects (AE) for electronic cigarette (e-cig) and refill liquid											
<u>'</u>			Patient	indiv	ridual data						
1. Initials or Record number 2. Year o				Sex □ M □ F	4. Wei	ght (kg)	5. Height (cm)				
6. Ethnicity/race (optional)			7.	Pregnancy Breastfeeding	□no □no	YES, we	eek				
			Desc	riptio	on of AE						
8 AF start (date)			9. Causes of AE								
o. At sign (gale)			☐ inhalation ☐ e-cig								
after e-cia use, specify after how lona:			more intense use of e-ci	ntense use of e-cig, describe							
10. Symptoms				11. If use of the e-cig was stopped did the AE stop?							
☐ throat irritation	hroat irritation \Box coughing up of blood			□ NO □ YES							
sore throat	☐ bleeding form	the nose	dizziness	12. Treatment of the AE							
dry mouth	anaphylaxis		☐ vertigo	□ NO □ YES							
mouth ulcers	☐ sweating		☐ tremors		Describe						
dry cough	abdominal pai	in	☐ restlessness								
☐ laryngospasm	high blood pre	ssure	☐ tachycardia								
☐ asthma	☐ vomiting		☐ bradycardia		13. Seriousnes	s of AE		14. Outcome			
shortness of breath	skin rash		apple eye irritation		D required a vie	it to dooto	-	discharged after doctor visit			
☐ bronchospasm	nausea		nose irritation		☐ required a visit to doctor☐ admitted to hospital		I	recovered.			
chest pain	diarrhoea		☐ burn and scalds		disability			how long			
worsening of pre-existi	na conditions:				☐ life threatening			☐ fatal(date)			
other	0							unknown			
15. Comments on causal relationships between e-cig and AE											
certain likely	possibile	山 un	likely 🖵 unrelated 🖵	UNKNO	own note						
16. Describe any oth	er detail (e.g. o	duration	of the AE, complicatio	ns/se	equelae and any	relevan	t laborato	ry results)			
				1	8. Use of E-cig c	ontaining					
17. Exclusive use of	e-cig ☐ YES	□ NO	If answered <u>NO</u> specify :		~	_					
dual user, how long_											
Duration of smoking before If user of other tobacco p	•			_	only flavours						
ii osei oi oinei iobacco p	roduct, specify			+	■ Triixed substances)		T			
19. Nicotine concentration (mg/ml):				20. Duration of e-cig use			21. Restart e-cig use after AE				
\square rechargeable e-cig (refillable through the e-liquid bo		ottle)					☐ YES ☐ NO				
			less than 1 month		2-3 mor	nths	Symptoms returned				
disposable e-cig			4-6 months \square more th		e than 6 m	onths	_				
☐ disposable cartridge INC							☐ YES ☐ NO				
22. Is the electronic	cigarette used	at the t	ime of the symptoms th	ne sa	me as normally (used?	YES	□ NO			
Specify the brand			Sales point	☐ spe	cialized seller 🔲 ph	narmacy (internet	☐ tobacconist ☐ retail seller ☐ other			
			☐ refill liquid ☐ self-made								
Specify the new brand	e-cia and/or liau	ıid)			Sales point i	f different					
								etc. used at the time of the			
·			<u>S</u> Specify		•	-	•				
Dosage, route of administration and duration of use:											
04 0		.1 1-1-1	. (!!!!!!				,				
24. Current or past re	elevant medica	ii nistory	(illnesses, allergies, al	cono	ı use, arugs of al	ouse, etc	.)				
											
			Do	la- !	form attem						
OF THE			кероп		formation	•					
25. Title					6. Contact detail	3					
general doctor	☐ pharmacist	t [nurse		Name + Surname						
hospital doctor	a consumer o	or his/her	carer		Address						
medical specialist	other_				Phone			Fax			
- medical specialist	-Olliel				E-mail						
27. date											